EUR-Lex & EU Commission AI-Powered Semantic Search Engine
Modern Legal
  • Query in any language with multilingual search
  • Access EUR-Lex and EU Commission case law
  • See relevant paragraphs highlighted instantly
Start free trial

Similar Documents

Explore similar documents to your case.

We Found Similar Cases for You

Sign up for free to view them and see the most relevant paragraphs highlighted.

Case T-416/22 R: Order of the President of the General Court of 18 October 2022 — Fresenius Kabi Austria and Others v Commission (Interim relief — Medicinal products for human use — Directive 2001/83/EC — Marketing authorisations for medicinal products containing the active substance ‘hydroxyethyl starch (HES), solutions for infusion’ — Application for suspension of operation of a measure — No urgency)

ECLI:EU:UNKNOWN:62022TB0416

62022TB0416

October 18, 2022
With Google you find a lot.
With us you find everything. Try it now!

I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!

Valentina R., lawyer

5.12.2022

Official Journal of the European Union

C 463/53

(Case T-416/22 R)

(Interim relief - Medicinal products for human use - Directive 2001/83/EC - Marketing authorisations for medicinal products containing the active substance ‘hydroxyethyl starch (HES), solutions for infusion’ - Application for suspension of operation of a measure - No urgency)

(2022/C 463/79)

Language of the case: English

Parties

Applicants: Fresenius Kabi Austria GmbH (Graz, Austria), and the 14 other applicants whose names are listed in the annex to the order (represented by: W. Rehmann and A. Knierim, lawyers)

Defendant: European Commission (represented by: M. Escobar Gómez and K. Mifsud-Bonnici, acting as Agents)

Re:

By their application under Articles 278 and 279 TFEU, the applicants seek the suspension of operation of European Commission Implementing Decision C(2022) 3591 final of 24 May 2022 concerning, in the framework of Article 107p of Directive 2001/83/EC of the European Parliament and of the Council, the marketing authorisations of medicinal products for human use which contain the active substance ‘hydroxyethyl starch (HES), solutions for infusion’ following an assessment of a post authorisation safety study.

Operative part of the order

1.The application for interim measures is dismissed.

2.The costs are reserved.

EurLex Case Law

AI-Powered Case Law Search

Query in any language with multilingual search
Access EUR-Lex and EU Commission case law
See relevant paragraphs highlighted instantly

Get Instant Answers to Your Legal Questions

Cancel your subscription anytime, no questions asked.Start 14-Day Free Trial

At Modern Legal, we’re building the world’s best search engine for legal professionals. Access EU and global case law with AI-powered precision, saving you time and delivering relevant insights instantly.

Contact Us

Tivolska cesta 48, 1000 Ljubljana, Slovenia